Phase 2 Trial of CBX-12, a Topoisomerase I Inhibitor, for Metastatic Colorectal Cancer

This trial evaluates CBX-12 given as a 60-minute IV infusion every 21 days in patients with chemotherapy-refractory, microsatellite stable metastatic colorectal cancer. Eligible participants include those with third-line disease, with or without BRAFV600 or RAS/RAF mutations. Sponsored by the National Cancer Institute, the study explores a novel peptide-delivered topoisomerase I inhibitor approach.